Nurix Therapeutics, Inc. (NASDAQ: NRIX) is a Healthcare company (Biotechnology) with a market capitalization of $1.7B. The Maz Rating grades it against the other companies in its sector.
About three months ago (July 2, 2026), Nurix Therapeutics, Inc. had a Maz Rating of 3.55 out of 5 (B+, Buy), ranked against the other companies in its sector. Its strongest factor then was Momentum (4.54), among the strongest in its sector; its weakest was Valuation (1.39), among the most expensive in its sector. The other factors: Growth 3.35 (around the middle of its sector); Financial Health 3.25 (around the middle of its sector); Profitability 2.26 (below most of its sector). The current rating is for members: log in to see it.
At $15.30, Nurix Therapeutics, Inc. trades at 6.1x trailing earnings, 2.4x sales and 1.8x book value, with an EV/EBITDA of 3.2. Over the last twelve months it generated about $702M of revenue and $274M of net income. It runs a gross margin of 86.5%, an operating margin of 41.3% and a net margin of 42.0%. It shows return on equity of 49.3%, return on invested capital of 26.0% and a free cash flow yield of 22.1%. On the balance sheet: a debt-to-equity ratio of 0.07 and a current ratio of 8.44. Over the past 52 weeks the share price ranged from $12.01 to $28.23, with a beta of 1.80.
Nurix Therapeutics, Inc. does not currently pay a dividend.
19 Wall Street analyst ratings cover the stock: 18 Buy and 1 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.